Synopsis of new antiangiogenetic factors, mutation compensation agents, and monoclonal antibodies in target therapies of breast cancer.
Breast cancer is the most common type of cancer among females and the 5th most common cause of cancer death. About 5-10% of breast cancers occur due to gene mutations inherited from mother or father. The molecular basis of breast cancer has been extensively investigated, making gene therapy a potential new therapeutic alternative. Mutation compensation, molecular chemotherapy, proapoptotic gene therapy, antiangiogenic gene therapy, genetic immunopotentiation and genetic modulation of resistance/sensitivity are the main gene therapies used. The combination of gene therapy with chemotherapy or radiation is being investigated in ongoing trials. The purpose of this review was to make a synopsis of the currently existing target therapies in breast cancer.